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SUMMARY 
Background The interleukin-23 pathway is implicated genetically and biologically in the pathogenesis 
of Crohn's disease. We aimed to assess the efficacy and safety of risankizumab (BI 655066, 
Boehringer Ingelheim, Ingelheim, Germany), a humanised monoclonal antibody targeting the p19 
subunit of interleukin-23, in patients with moderately-to-severely active Crohn's disease. 
Methods In this randomised, double-blind, placebo-controlled phase 2 study, we enrolled patients at 
36 referral sites in North America, Europe, and south-east Asia. Eligible patients were aged 18-75 
years, with a diagnosis of Crohn's disease for at least 3 months, assessed as moderate-to-severe 
Crohn's disease at screening, defined as a Crohn's Disease Activity Index (CDAI) of 220-450, with 
mucosal ulcers in the ileum or colon, or both, and a Crohn's Disease Endoscopic Index of Severity 
(CDEIS) of at least 7 (≥4 for patients with isolated ileitis) on ileocolonoscopy scored by a masked 
central reader. Patients were randomised 1:1:1 using an interactive response system to a double-blind 
investigational product, and stratified by previous exposure to TNF antagonists (yes vs no). Patients 
received intravenous 200 mg risankizumab, 600 mg risankizumab, or placebo, at weeks 0, 4, and 8. 
The primary outcome was clinical remission (CDAI <150) at week 12 (intention-to-treat population). 
Safety was assessed in patients who received at least one dose of study drug. This study is registered 
with ClinicalTrials.gov, number NCT02031276. 
Findings Between March, 2014, and September, 2015, 213 patients were screened, and 121 patients 
randomised. At baseline, 113 patients (93%) had been previously treated with at least one tumour 
necrosis factor (TNF) antagonist (which had failed in 96 [79%]). At week 12, 25 (31%) of 82 
risankizumab patients (pooled 41 patients in 200 mg and 41 patients in 600 mg arms) had clinical 
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remission versus six (15%) of 39 placebo patients (difference vs placebo 15 · 0%, 95% CI 0•1 to 30-1; 
p=0∙0489). Ten (24%) of 41 patients who received 200 mg risankizumab had clinical remission (9-0%, 
-8-3 to 26-2; p=0∙31) and 15 (37%) of 41 who received the 600 mg dose (20∙9%, 2∙6 to 39∙2; 
p=0∙0252). 95 (79%) patients had adverse events (32 in the placebo group, 32 randomised to 200 mg 
risankizumab, 31 randomised to 600 mg risankizumab); 18 had severe adverse events (nine, six, 
three); 12 discontinued (six, five, one); 24 had serious adverse events (12, nine, three). The most 
common adverse event was nausea and most common serious adverse event was worsening of 
underlying Crohn's disease. No deaths occurred. 
Interpretation In this short-term study, risankizumab was more effective than placebo for inducing 
clinical remission in patients with active Crohn's disease. Therefore, selective blockade of interleukin-
23 via inhibition of p19 might be a viable therapeutic approach in Crohn's disease. 
Research in context 
EVIDENCE BEFORE THIS STUDY 
We searched PubMed for English language articles using the terms "Crohn's disease", 
"biologictherapy", "adalimumab", "infliximab", "certolizumab pegol", "vedolizumab", "ustekinumab", and 
"IL-23" to identify controlled clinical trials published up to June 17,2016, with no start date restrictions. 
Biological therapies approved for Crohn's disease include the tumour necrosis factor (TNF) 
antagonists adalimumab, infliximab, and certolizumab pegol. Treatment with these drugs has resulted 
in some induction of clinical remission inTNF antagonist-naive patients. Treatment with a secondTNF 
antagonist is effective in patients who have lost response or were intolerant to their previous TNF 
antagonist, but a response to a second TNF antagonist after primary TNF antagonist failure is not well 
studied and is generally very low. The integrin inhibitor vedolizumab has been approved for Crohn's 
disease. 
The interleukin-23 pathway is implicated in the pathogenesis of psoriasis and Crohn's disease. 
Biological agents that abrogate this axis, through targeted inhibition of interleukin 17 orthe interleukin 
17 receptor, interleukin 23, or interleukin 12 and interleukin 23, have shown efficacy in clinical trials for 
the treatment of psoriasis. 
ADDED VALUE OF THIS STUDY 
In this proof-of-concept phase 2 clinical trial for risankizumab, a monoclonal antibody that targets the 
interleukin-23 p19 subunit, in treatment-experienced patients with moderate-to-severe Crohn's 
disease, risankizumab was superiorto placebo in achieving clinical response or remission at week 12 
in patients with moderate-to-severe Crohn's disease. 
IMPLICATIONS OF ALL THE AVAILABLE EVIDENCE 
Biological agents that abrogate the interleukin-23 pathway axis have shown efficacy in clinical trials for 
the treatment of psoriasis, but agents that specifically target interleukin 17 or the interleukin 17 
receptor exacerbate Crohn's disease, indicating a dichotomy between the activity of interleukin 12/ 
interleukin 23 and interleukin 17 in psoriasis versus Crohn's disease. Ourtrial of risankizumab in 
treatment-experienced patients with moderate-to-severe Crohn's disease suggests that specific 
blockade of interleukin 23 with risankizumab might be a promising new therapeutic approach with a 
unique mode of action forthe treatment of this serious chronic disease. 
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Introduction 
Crohn's disease is a chronic inflammatory bowel disease characterised by ulceration and transmural 
inflammation.
1
 Management consists of controlling inflammation through administration of broadly 
acting immunosuppressive drugs such as corticosteroids, thiopurines, or methotrexate, or selective 
targeting of cytokines or integrins with biological agents.
2-4
 These therapies are not consistently 
effective and can cause adverse events including infection.
4-6
 About a third of patients treated with a 
TNF antagonist show a primary non-response, with another third developing secondary failure or 
intolerance to treatment. Patients with primary non-response or secondary failure to a TNF antagonist 
have a lower chance of responding to subsequent treatment with different TNF antagonists or the 
integrin antagonist vedolizumab. 
Interleukin-23 receptor gene polymorphisms are associated with susceptibility to Crohn's disease, and 
interleukin-23 is a key regulator of the T-helper-17 cell (Thl7) and type 3 innate lymphoid cell (ILC3) 
pathways that contribute to inflammatory cytokine production and tissue inflammation.
7-9
 The 
interleukin-23 pathway is implicated in the pathogenesis of several immune-mediated chronic 
inflammatory diseases including psoriasis and Crohn's disease. Biological agents that abrogate this 
axis, either through targeted inhibition of the interleukin-17/interleukin-17 receptor (brodalumab, 
ixekizumab, secukinumab), interleukin-23 (guselkumab, risankizumab, tildrakizumab), or interleukin-12 
and interleukin-23 (ustekinumab), have shown efficacy in clinical trials for the treatment of psoriasis.
10
 
In Crohn's disease, interleukin 12 and interleukin-23 p40 subunit inhibition by ustekinumab appears 
beneficial with effect sizes for induction of clinical remission of 9-18% in patients with previous tumour 
necrosis factor (TNF) antagonist failure and 23-27% in TNF-antagonist-experienced patients.
11,12
 
However, whether its efficacy is driven by the inhibition of interleukin-12, interleukin-23, or both 
cytokines, is unclear. In the absence of direct comparator trials, these effect sizes must be interpreted 
with caution while considering the differences in study population and design that affect such cross-
trial comparison. By contrast, agents that specifically target interleukin-17 or interleukin-17 receptor 
exacerbate Crohn's disease, indicating a dichotomy between the activity of interleukin-12/interleukin-
23 and interleukin-17 in psoriasis versus Crohn's disease.
13,14
 To our knowledge, no treatments that 
specifically target interleukin-23 in Crohn's disease are approved and only limited   clinical   trial   data   
for   such   agents   exist. 
Risankizumab (BI 655066, Boehringer Ingelheim, Ingelheim, Germany) is a humanised monoclonal 
antibody that targets the pl9 subunit, which is specific to interleukin-23.
15
 Thus, treatment with 
risankizumab might downregulate interleukin-23-mediated inflammation without affecting interleukin-
12-dependent T-cell pathways which, in animal models, are important for infection and cancer 
immunity.
16,17
 This selective approach might have advantages over agents that target both cytokines. 
Preliminary data indicate that risankizumab is an effective treatment for psoriasis, a chronic 
inflammatory skin disease in which the interleukin-23 pathway is implicated.
18
 On the basis of these 




In this multicentre, randomised, placebo-controlled, phase 2 study, we enrolled patients at 36 referral 
sites in North America, Europe, and southeast Asia (appendix). The study had three treatment 
periods: a 12-week double-blinded intravenous therapy period (period 1); a 12-week open-label 
intravenous therapy or wash-out period (period 2); and a 26-week subcutaneous therapy period 
(period 3). We report the primary, secondary, and additional endpoints—including biomarker, 
pharmacokinetic, and anti-drug antibody assessments—for period 1; endpoints for periods 2 and 3 will 
be reported after completion of the study. The complete study design is shown in the appendix (p7). 
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The study protocol was approved by the institutional review board or ethics committee at each 
participating centre. Safety data were periodically evaluated by an independent data monitoring 
committee. 
PATIENTS 
Eligible patients were aged 18-75 years, with a diagnosis of Crohn's disease for at least 3 months that 
was assessed as moderate-to-severe Crohn's disease at screening, defined as a Crohn's Disease 
Activity Index (CDAI)19 of 220-450, with mucosal ulcers in the ileum or colon, or both, and a Crohn's 
Disease Endoscopic Index of Severity (CDEIS)19 of at least 7 (≥4 for patients with isolated ileitis) on 
ileocolonoscopy scored by a masked central reader (descriptions of CDAI and CDEIS are in the 
appendix, p 5). Patients could have had previous treatment with one or more tumour necrosis factor 
(TNF) antagonists or vedolizumab. Patients previously treated with ustekinumab were excluded, as 
were patients who had received any other biological agent (including agents targeting integrins) within 
8 weeks or five half-lives before randomisation. Patients continued stable doses of oral corticosteroids, 
oral 5-aminosalicylates, azathioprine, 6-mercaptopurine, methotrexate, and antibiotics throughout the 
trial if they were on these at the start. A full description of the inclusion and exclusion criteria is in the 
appendix (pp 3-4). All patients provided written informed consent. 
RANDOMISATION AND MASKING 
Before the first 12-week period, we randomly assigned patients (1:1:1) to receive 200 mg 
risankizumab, 600 mg risankizumab, or placebo. We used an interactive response system to assign a 
double-blind investigational product to every patient. Randomisation was stratified by previous 
exposure to TNF antagonists (yes vs no). A randomisation list was generated using a validated 
system, which involved a pseudorandom number generator to guarantee the reproducibility of the 
assignments. This randomisation list was checked by an independent statistician and used to assign 
randomisation numbers to eligible patients. Access to the randomisation code was controlled and 
documented. All people directly involved in the conduct and analysis of the trial (including patients, 
investigators, and study personnel) were fully masked to the treatment allocation before the week 12 
database lock. To maintain masking, study drug packaging was identical irrespective of treatment and 
was only distinguishable by medication number, which was managed by the central randomisation 
centre. Both risankizumab and placebo appeared as clear solutions. 
PROCEDURES 
Patients received either 200 mg risankizumab, 600 mg risankizumab, or placebo by intravenous 
infusion at weeks 0, 4, and 8 (appendix, p 7). Patients were followed through week 12, every 4 weeks, 
and were then eligible to enter subsequent phases of the trial. 
OUTCOMES 
The primary outcome was clinical remission in the pooled risankizumab dose groups, defined by a 
CDAI <150 at week 12. Secondary outcomes (all evaluated at week 12) including clinical response 
(defined by either CDAI <150 or a CDAI reduction from baseline of ≥100), endoscopic remission 
(CDEIS score of ≤4; ≤2 for patients with isolated ileitis), endoscopic response (>50% CDEIS reduction 
from baseline), mucosal healing (absence of mucosal ulceration), and deep remission (clinical 
remission and endoscopic remission) are reported here. All further endpoints relating to period 1 are 
listed in the appendix (p 4) and will be reported after completion of the study. Of these, we report CDAI 
throughout period 1, change from baseline to week 12 in Inflammatory Bowel Disease Questionnaire 
(IBDQ), C-reactive protein (CRP) throughout period 1, and percentage change from baseline in faecal 
calprotectin (FCP). Additionally, percentage change from baseline in serum interleukin 22 was 
reported because activated T helper 17 and ILC3 cells from patients with inflammatory bowel disease 
characteristically produce interleukin 22, as well as biomarker gene changes to week 12, 
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pharmacokinetic data (where data permitted), and anti-drug antibody assessments. Additional post-
hoc analyses were the proportion of patients achieving normalisation of CRP and FCP. 
Health-related quality of life (HRQoL) was assessed at baseline and at week 12 by asking patients to 
complete the 32 questions of the IBDQ, which has been established as a valid, reliable, and 
responsive tool to scale the impact of bowel-related symptoms, systemic complaints, social functions, 
and emotional status of patients with ulcerative colitis, with higher scores indicating better HRQoL.20 
At each study visit, data were obtained for CDAI, adverse events, concomitant medications, FCP, and 
serum CRP concentration. Biomarkers relevant to the interleukin 23 pathway were evaluated in tissue 
biopsies obtained at baseline and at week 12, and in whole blood samples (appendix p 5). CDEIS 
scores and presence or absence of mucosal ulcers were determined by masked central readers at 
baseline and week 12. Plasma samples for pharmacokinetic analysis and immunogenicity 
assessments were collected at each visit. The schedule for collection and assay methodology is 
described in the appendix (pp 4—5). The anti-drug antibody electro-chemiluminescence assay was 
sensitive and drug tolerant. 
Safety endpoints were adverse events (coded using version 18.1 of the Medical Dictionary for Drug 
Regulatory Activities [MedDRA], severity grading based on   the    Rheumatology    Common    
Toxicity    Criteria version 2.0), serious adverse events, tolerability changes in vital signs and physical 
examination, discontinuation of therapy because of adverse events, and laboratory assessments. 
 
Figure 1: Trial profile 
 
STATISTICAL ANALYSIS 
We analysed the primary and secondary endpoints on an intention-to-treat basis. Pharmacokinetic 
data, immuno-genicity and biomarker endpoints were analysed on all evaluable patients who received 
at least one dose of study drug. Differences in pairwise comparisons for the primary and secondary 
endpoints were analysed using a stratified Cochran-Mantel-Haenszel test, with previous exposure to 
TNF antagonists as the stratification variable; confidence intervals were calculated by normal 
approximation of the variance of Mantel-Haenszel stratified risk difference. Continuous outcomes 
including change or percentage change from baseline in CDAI, CRP, FCP, and plasma interleukin-22 
concentrations were summarised descriptively and baseline values were assigned from time of 
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treatment initiation; a Wilcoxon two-sample test was used post hoc to compare the median differences 
from baseline between treatments. 
We predicted that both the 200 mg risankizumab and 600 mg risankizumab dose groups would be 
effective; thus, the primary analysis was based on a comparison of week 12 remission rates in the 
pooled risankizumab dose groups with placebo. We estimated that randomisation of 120 patients in a 
2:1 ratio between risankizumab (200 mg and 600 mg, pooled) and placebo would provide 82% power 
using a two-sided test with a type 1 error of 0·10, which we used to increase the sensitivity of 
identifying a treatment effect for the primary endpoint. A 30% clinical remission rate for the combined 
risankizumab dose groups and a 9% rate for placebo was the basis for the calculation. For secondary 
endpoints, statistical significance was based on two-sided p values less than 0·05. Non-response 
imputation was used for missing values and analysis. Patients missing their week 12 CDEIS 
assessment were counted as endoscopic failures; patients in whom prohibited concomitant medication 
to treat Crohn's disease was used before week 12 and those with missing CDAI items were 
considered to be treatment failures. We did not adjust for multiplicity for clinical and endoscopic 
endpoints; for RNA biomarker analyses, we applied the Bonferroni's correction for multiple 
comparisons. 
Safety analyses included patients who underwent randomisation and received at least one dose of 
study drug. We report frequencies of adverse events descriptively. This trial is registered with 
ClinicalTrials. gov, number NCT02031276. 
ROLE OF THE FUNDING SOURCE 
The funder of the study was involved in the study design and the data collection and analysis. All 
authors had full access to all data in the study, made the decision to submit these data for publication, 
were involved in writing the manuscript, and agreed upon the final content of the paper. The study 
funder provided funding for editorial assistance in manuscript preparation. The corresponding author 
had final responsibility for the decision to submit for publication. 
Results 
Between March, 2014, and September, 2015, 213 patients were screened and 121 were randomised 
(figure 1). The main reason for screening failures was insufficient clinical or endoscopic activity. Less 
frequent reasons included the presence of Crohn's complications, concomitant diseases, or insufficient 
wash-out time of prohibited medications. 13 patients discontinued study participation before week 12 
(figure 1). Baseline demographics and disease characteristics of patients were similar in treatment 
groups (table 1). Mean duration of Crohn's disease was 13 years (SD 9) at study entry. 
Clinical remission at week 12 was achieved by ten (24%) of 41 patients in the 200 mg risankizumab 
group and 15 (37%) of 41 patients in the 600 mg risankizumab group, compared with six patients 
(15%) in the placebo group (figure 2, table 2). At week 12, the observed difference between the 
pooled risankizumab dose groups and placebo was 15·0% (95% CI 0·1 to 30·1; p=0·0489). The 
observed difference between the 200 mg risankizumab arm and placebo was 9·0% (95% CI -8·3 to 
26·2, p=0∙31; table 2) and between the 600 mg risankizumab arm and placebo was 20·9% (2·6 to 
39·2, p=0∙0252; table 2). The difference in clinical remission between risankizumab and placebo at 
week 8 was 14·5% (2·0 to 27·0; ρ=0·0228) in the 200 mg risankizumab arm and 21·7% (7·7 to 35·7; 
p=0∙0023) in the 600 mg risankizumab arm (figure 2, table 2). 
The proportion of patients with clinical response, endoscopic response, or deep remission at week 12 
did not differ between the 200 mg risankizumab group and placebo but an increased proportion of 
patients in the 600 mg risankizumab group had these outcomes (figure 2, table 2). An increased 
proportion of patients had clinical response at week 8 with both risankizumab doses. More patients 
had endoscopic remission at week 12 in the 200 mg and 600 mg risankizumab dose groups compared 
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with placebo (table 2). The proportion of patients with mucosal healing did not differ between 
risankizumab treatment and placebo (table 2). 
The IBDQ assessment indicated a reduced HRQoL of the randomised study population at baseline. 
Treatment with risankizumab resulted in a dose-dependent increase from baseline to week 12 by 7·3 
points for placebo, 21·7 points for 200 mg risankizumab, and 34·7 points for 600 mg risankizumab 
(difference for 600 mg risankizumab vs placebo 27·3, 95% CI 11·7 to 43·0, p=0∙0009; appendix, p 8). 
Median CRP concentrations were reduced in both risankizumab arms compared with placebo at week 
12 (-6·2 mg/L [IQR -17·0 to 0·2] for 200 mg risankizumab, -2·8 mg/L [-22·2 to -0·1] for 600 mg 
risankizumab, vs 2·7 mg/L [-1·2 to 10·1] or placebo; ρ<0·0001 for each arm vs placebo; figure 3). In 
the post-hoc analysis, normalisation of CRP to less than the upper limit of normal (2·87 mg/L) at week 
12 in patients with elevated CRP at baseline was observed in eight (24%) of 33 patients who received 
200 mg risankizumab, eight (29%) of 28 patients in the 600 mg risankizumab arm, and two (7%) of 28 
patients in the placebo arm. Treatment with 600 mg risankizumab decreased median FCP levels 
compared with placebo (median % change from baseline to week 12 -74·4% [IQR -91·7 to -1·0] vs -
2·5% [-55·5 to 107·1], p=0∙0003; figure 3). In the post-hoc analysis, normalisation of FCP to less than 
the upper limit of normal (50 µg/g) at week 12 in patients with elevated FCP at baseline was observed 
in one (3%) of 29 patients in the 200 mg risankizumab arm, five (16%) of 31 patients in the 600 mg 
risankizumab arm, and two (7%) of 30 patients in the placebo arm. Additionally, plasma interleukin-22 
concentration was lower with 600 mg risankizumab treatment than with placebo (median % change 
from baseline to week 12 -44∙2 [IQR-58∙8 to-14∙3] vs-16∙7 [IQR-39∙0 to 36∙8]; p=0∙0180; figure 3). 
Colon or ileum tissue was collected at baseline and at week 12 from a subset of patients (26 [63%] for 
colon and 30 [73%] for ileum in the 200 mg risankizumab group; 27 [66%] for colon and 26 [63%] for 
ileum in the 600 mg risankizumab group; and 26 [67%] for colon and 22 [56%] for ileum in the placebo 
group). Significant reductions in the expression of selected genes associated with interleukin-23 
immune-related pathways were observed in the colon biopsies of this subset of risankizumab-treated 
patients compared with placebo (appendix, p 9). 
Interleukin-22 gene expression was significantly reduced from baseline to week 12 in the ileum 
biopsies from the subset of pooled risankizumab-treated patients (log2 fold change -1∙94; p=0∙003; 
appendix p 9). 
No dose-related increases for any adverse events were associated with risankizumab treatment (table 
3). The most frequent adverse events were associated with the gastrointestinal tract. The most 
common serious adverse event was worsening of underlying Crohn's disease (appendix p 15). No 
deaths occurred, although serious infections were reported in three patients (abdominal, anal, and 
rectal abscesses, and pneumonia) in the placebo arm, one patient (pneumonia) in the 200 mg 
risankizumab group, and two patients (osteomyelitis and anal abscess) in the 600 mg risankizumab 
group (appendix p 15). Infusion-related reactions were mild or moderate and were reported in two 
(5%) patients in the placebo group and one (2%) patient in each of the 200 mg and 600 mg 
risankizumab groups. No differences between treatment groups were observed in physical 
examination, vital signs, electrocardiograph monitoring, and safety laboratory analyses. 
Treatment-emergent anti-drug antibodies were detected in 4% of patients receiving risankizumab 
(three of 76 patients). Anti-drug antibody titre values were low (≤8) and no neutralising antibodies were 
detected. Preexisting anti-drug antibodies were observed in five patients in the risankizumab dose 
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Age (years) 36 (14) 39 (13) 40 (13) 39 (13) 
Sex 
 Male 16 (41%) 15 (37%) 16 (39%) 31 (38%) 
 Female 23 (59%) 26 (63%) 25 (61%) 51 (62%) 
White 32 (82%) 36 (88%) 34 (83%) 70 (85%) 
Bodyweight (kg) 68 (22) 66 (15) 67(13) 67 (14) 
Current smoker 7(18%) 12 (29%) 13 (32%) 25 (30%) 
Duration of disease, years 12 (9) 14(9) 14 (10) 14(9) 
Disease site 
 Ileum only 5 (13%) 6(15%) 10 (24%) 16 (20%) 
 Ileum and colon 16 (41%) 25 (61%) 16 (39%) 41 (50%) 
 Colon only 18 (46%) 10 (24%) 14 (34%) 24 (29%) 
History of fistulising disease 9 (23%) 7 (17%) 5 (12%) 12 (15%) 
Draining fistulae at baseline 0 2 (5%) 2(5%) 4(5%) 
Previous intestinal resection for Crohn's disease 1(3%) 0 1(2%) 1 (1%) 





CDEIS 11 (8-18) 12 (9-17) 12 (8-16) 12 (9-17) 









Haemoglobin (g/L) 125 (17) 126 (15) 127 (15) 126 (14) 
Corticosteroids or IM, or both 
 Corticosteroids only 6(15%) 7 (17%) 9 (22%) 16 (20%) 
 Corticosteroids and IM 5 (13%) 3 (7%) 3 (7%) 6 (7%) 
 IM only 8 (21%) 7 (17%) 5 (12%) 12 (15%) 
Previous TNF antagonist use 
 1 12 (31%) 9 (22%) 9 (22%) 18 (22%) 
 2 20 (51%) 23 (56%) 24 (59%) 47 (57%) 
 ≥3 5 (13%) 7(17%) 4 (10%) 11 (13%) 
 Missing 2 (5%) 2 (5%) 4 (10%) 6 (7%) 
Worst outcome of ≥1 previous TNF antagonists 
 Inadequate response 10 (26%) 16 (39%) 11 (27%) 27(33%) 
 Loss of response 21 (54%) 13 (32%) 17 (41%) 30 (37%) 
 Unacceptable adverse events 1(3%) 2 (5%) 5 (12%) 7(9%) 
 Other 2 (5%) 3 (7%) 1(2%) 4(5%) 
 Unknown 1(3%) 3 (7%) 2 (5%) 5 (6%) 
Data are mean (SD), n (%), or median (IQR). CDAI=Crohn's Disease Activity Index. CDEIS=Crohn's Disease 
Endoscopic Index of Severity. CRP=C-reactive protein. FCP=faecal calprotectin. IM=immunomodulators. 
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200 mg (n=41) 600 mg (n=41) Pooled (n=82) 
Clinical remission (primary endpoint) 
η(%) 6 (15%) 10 (24%) 15 (37%) 25 (31%) 
 Difference vs placebo 
(95% CI, p value) 
 9∙0% (-8∙3to 26∙2, 
p=0∙31) 
20∙9% (2∙6 to 39∙2, 
p=0∙0252) 
15∙1% (0∙1 to 30∙1, 
p=0∙0489) 
Clinical response (secondary endpoint) 
η(%) 8 (21%) 15 (37%) 17(42%) 32 (39%) 
 Difference vs placebo 
(95% CI, p value) 
 16∙0% (-3∙2 to 35∙2, 
ρ=0∙10) 
20∙3% (1∙3 to 39∙4, 
p=0∙0366) 
18∙4% (2∙1 to 34∙8, 
p=0∙0273) 
Endoscopic remission (secondary endpoint) 
η(%) 1(3%) 6 (15%) 8 (20%) 14 (17%) 
 Difference vs placebo 
(95% CI, p value) 
 12∙1% (0∙8 to 23∙4, 
p=0∙0357) 




Endoscopic response (secondary endpoint) 
η(%) 5 (13%) 11 (27%) 15 (37%) 26 (32%) 
 Difference vs placebo 
(95% CI, p value) 
 141% (-2∙8 to 30∙9, 
ρ=0∙10) 
23-5% (5∙5 to 41∙5, 
ρ=0∙0106) 
18∙7% (4∙4 to 33∙0, 
p=0∙0104) 
Mucosal healing (secondary endpoint) 
η(%) 1(3%) 1(2%) 3 (7%) 4(5%) 
Difference vs placebo 
(95% CI, p value) 
 -0∙1%(-7∙0 to 
6∙7,p=0∙97) 
4∙9% (-4∙6to 14∙3, 
p=0∙31) 
24%(-45to9∙2,p=0∙50) 
Deep remission (secondary endpoint) 
η(%) 0 1(2%) 5 (12%) 6 (7%) 
 Difference vs placebo 
(95% CI, p value) 
 2∙4%(-2∙3 to 
7∙1,p=0∙31) 
124% (2∙3 to 22∙5, 
p=0∙164) 
7∙4% (1∙7to 13∙0, 
p=0∙0107) 
Clinical remission is defined as a CDAI score <150. Clinical response is either a CDAI score <150 or a CDAI 
reduction of ≥100 from baseline. Endoscopic remission is a CDEIS score of ≤4 at week 12 (≤2 for patients with 
initial isolated ileitis). Endoscopic response is a >50% reduction in CDEIS score from baseline to week 12. 
Mucosal healing is defined as the absence of mucosal ulceration. Deep remission is clinical remission and 
endoscopic remission. Full analysis set was used for this analysis, using non-response imputation for missing 
values and stratified Cochran-Mantel-Haenszel tests. CDAI=Crohn's Disease Activity Index. CDEIS=Crohn's 
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Figure 2: Clinical response and remission over 12 weeks 
Proportion of patients with clinical remission (A) or clinical response (B). Clinical remission is defined as a CDAI 
score <150. Clinical response is either a CDAI score <150 or a CDAI reduction of ≥100 from baseline. Patients in 
whom prohibited concomitant medication to treat Crohn's disease was used before week 12 were considered as 
treatment failures. Intention-to-treat group was used for this analysis, using non-response imputation for missing 
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Table 3: Adverse events (on treatment at week 12) 
 Placebo (n=39) Risankizumab 
200 mg (n=41) 600 mg (n=41) 
Any adverse event 32 (82%) 32 (78%) 31 (76%) 
   Severe 9 (23%) 6(15%) 3 (7%) 
   Drug related 8 (21%) 10 (24%) 5 (12%) 
   Leading to discontinuation 6(15%) 5 (12%) 1(2%) 
Serious adverse events* 12 (31%) 9 (22%) 3 (7%) 
   Persistent or significant disability or       
incapacity 
0 1(2%) 0 
   Requiring or prolonging hospitalisation 10 (26%) 8 (20%) 2 (5%) 
   Other medically important serious 
event 
4 (10%) 1(2%) 1(2%) 
Common adverse events
†
    
   Nausea 4 (10%) 8 (20%) 3 (7%) 
   Worsening of Crohn's disease 6(15%) 2(5%) 0 
   Abdominal pain 4 (10%) 6(15%) 3 (7%) 
   Arthralgia 3 (8%) 6(15%) 6 (15%) 
   Anaemia 4 (10%) 0 2 (5%) 
   Headache 4 (10%) 6(15%) 4 (10%) 
   Vomiting 4 (10%) 3 (7%) 2 (5%) 
Data are n (%). *A serious adverse event was defined as any that results in death, is immediately life-threatening, 
results in persistent or significant disability or incapacity, requires or prolongs patient hospital stay, is a congenital 
anomaly or birth defect, or is an important medical event, based upon appropriate medical judgment that might 
jeopardise the patient and might require medical or surgical intervention. †Common adverse events were those 
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Figure 3: Change from baseline in CDAI and selected biomarkers Median CDAI (A), median CRP (B), 
median percentage change from baseline in FCP (C), and median percentage change from baseline in serum interleukin 22 (D). 
Bars are IQR. BL=baseline. CDAI=Crohn's Disease Activity Index. CRP=C-reactive protein. FCP=faecal calprotectin.*ρ<0∙0001 
for change from baseline in CRP for versus placebo. †p=0∙0003 for median percentage change from baseline in FCP versus 
placebo. ‡ρ=0∙0160 for median percentage change from baseline in serum interleukin 22 versus placebo 
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Discussion 
Despite the introduction of biological therapies, an unmet need exists for patients with moderate-to-
severe Crohn's disease because of high rates of treatment failure with conventional and biological 
therapies.
21,22
 About a third of patients treated with a TNF antagonist have a primary non-response, 
and another third develop secondary failure or intolerance to treatment.
4
 Patients who have had a 
primary non-response or secondary failure to a TNF antagonist have a lower chance of responding to 
subsequent treatment with different TNF antagonists
23
 or the integrin antagonist vedolizumab.
24 
Those 
patients who do not respond to the second-line biological therapy are at higher risk for poor outcomes. 
In this phase 2 trial, selective inhibition of interleukin-23 with risankizumab was superior to placebo in 
achieving clinical remission and response at week 12 in patients with moderate-to-severe treatment-
refractory Crohn's disease. 
The differences observed for clinical response and remission between the pooled risankizumab 
groups and placebo were statistically significant but were also clinically meaningful in this treatment-
refractory population, in which 83 (69%) of 121 patients had previously been exposed to at least two 
TNF antagonists and 96 (79%) of 121 patients had failed at least one such treatment (because of 
inadequate response, loss of response, or intolerance). The difference for the 600 mg dose achieving 
clinical remission compared with placebo was 20.9% (p=0.025), which represents a benefit similar to 
those reported for induction with infliximab or adalimumab in TNF antagonist-naive patients.
25,26
 
Although the near resolution of symptoms associated with Crohn's disease assessed as clinical 
remission represents one important treatment target, clinical activity in Crohn's disease correlates 
poorly with objective signs of gut inflammation.
27
 Because chronic inflammation can lead to long-term 
complications such as   strictures,   fistulae,   and   dysplasia,   we   included endoscopic assessments 
in this trial to assess objectively the effects of treatment on the inflammatory process. In accordance 
with the observed clinical endpoints, the observed rates of endoscopic remission and deep remission, 
which are challenging endpoints to meet in a short-term induction study,
28
 also indicate the superiority 
of the high-dose regimen versus the lower-dose regimen and placebo. 
We also found clinically meaningful increases in IBDQ for risankizumab compared with placebo. A 
mean change of 16 points is considered clinically meaningful for the IBDQ score
20
 and both the 200 
mg and 600 mg risankizumab groups exceeded this threshold, with 600 mg risankizumab statistically 
significant versus placebo. 
Both dose levels that we tested for induction in Crohn's disease were several times higher than those 
tested in plaque psoriasis, for which risankizumab regimens of 90 mg and 180 mg given 
subcutaneously at weeks 0, 4, and 12 showed superior efficacy versus ustekinumab at 12 weeks in a 
phase 2 study.
29
 Our dose selection was based on observations with TNF antagonists that indicated 
the need for higher induction doses in Crohn's disease compared with other indications, which might 
result from lower drug exposure because of intestinal protein loss or a larger burden of target 
molecules in the inflamed gut in inflammatory bowel diseases, or both.
30,31
 In keeping with this 
hypothesis, all efficacy outcomes favoured the 600 mg dose. The observed associations between 
risankizumab exposure and CDAI response and remission as well as endoscopic activity (CDEIS 
response) should be evaluated in future studies. 
Reductions in expression of biomarkers in blood and tissue were consistent with blockade of 
interleukin-23-mediated gut inflammation.
7
 Larger decreases in serum CRP and FCP concentrations 
were observed at 12 weeks in the risankizumab groups in comparison with the placebo group. 
Changes in gene expression observed in colon tissue indicated that multiple pathways associated with 
the interleukin-23 axis weredownregulatedbyl2weeks in patients treated with risankizumab. Activated 
Thl7 and ILC3 cells from patients with inflammatory bowel disease characteristically produce 
interleukin-22,
932
 and treatment with risankizumab decreased interleukin-22 expression in ileum 
biopsies and in circulation, consistent with the expected effects of blockade of the interleukin-23 axis. 
Collectively, these data suggest that selective inhibition of interleukin-23 through targeting of the 
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interleukin-23 pl9 subunit might be an effective induction therapy for moderate-to-severe Crohn's 
disease. 
In this short-term trial, risankizumab showed a favourable safety profile. We observed no association 
between drug dose and the incidence of adverse events, and we detected no dose-dependent safety 
signal. The most common serious adverse event was worsening of underlying Crohn's disease. 
However, the limited duration of the trial and the small number of patients evaluated did not allow an 
exhaustive assessment of the safety and tolerability of the drug. Treatment-emergent anti-drug 
antibodies were detected in 4% of patients but were of low titres and were not neutralising. The 
observation of low titre pre-existing anti-drug antibodies in eight patients is not unusual using highly 
sensitive assays and such antibodies are not usually clinically relevant.
33
 
A key strength of this study was its design. To be enrolled, patients needed to have baseline clinical 
and endoscopic activity, which was scored using central reading by a masked reviewer. Endoscopic 
outcome was also assessed in all patients as a secondary endpoint. 
The major limitations of our study were the low number of patients evaluated, resulting in relatively 
imprecise estimates of treatment effects, and the short study duration. Although the small number of 
TNF antagonist-naive patients randomised in this trial precludes the extrapolation of the observed 
effects beyond the study population, past trials
12,23
 in TNF antagonist-experienced patients with 
different biological treatments have generally shown a lower treatment effect in TNF antagonist-naive 
patients. Another methodological limitation inherent to all clinical trials in patients with Crohn's disease 
is the lack of clinical validation of endoscopic endpoints. However, the operating properties of the 
CDEIS used in this study are well characterised and have been successfully used in previous clinical 
trials.
34




In this short-term proof-of-concept trial in patients with moderate-to-severe Crohn's disease, in most of 
whom treatment with a TNF antagonist had previously failed, treatment with risankizumab achieved 
higher clinical and endoscopic remission rates than placebo at week 12. These results suggest that 
specific blockade of interleukin-23 via inhibition of pl9 might be a viable therapeutic approach in 
Crohn's disease and warrants further investigation in larger studies with longer duration. 
Contributors 
BGF wrote the initial draft. All authors approved the manuscript for submission and vouch for the 
veracity and completeness of the data and the fidelity of the study to the protocol. The study site and 
investigator details are in the appendix (p 2). BGF, WJS, GD'H, JP, AK, SS, PS, SV, SJP, DBH, and 
WOB contributed to study design. BGF, WJS, GD'H, JP, AK, MF, EL, DF, OD, US, K-JK, MFN, and 
SS contributed to data collection. All listed authors contributed to data analysis, data interpretation, 
and writing and review of the manuscript. 
Declaration of interests 
BGF reports personal fees from Receptos, during the conduct of the study; grants from Sanofi; grants 
and personal fees from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Janssen 
Biotech/Centocor, Johnson & Johnson/Janssen, Pfizer, Receptos, and Takeda; personal fees from 
Actogenix, Akros, Albireo Pharma, Allergan, Avaxia Biologies Inc, Avir Pharma, Axcan, Baxter 
Healthcare Corporation, Biogen Idee, Boehringer Ingelheim, Calypso Biotech, Celgene, Elan/Biogen, 
enGene, Ferring, Genentech/Roche, GiCare Pharma, Gilead, Given Imaging, GlaxoSmithKline, 
Ironwood, Kyowa Hakko Kirin Co, Ltd, Lilly, Lycera Biotech, Merck, Mesoblast Pharma, Millennium, 
Nestlé, Novo Nordisk, Novartis, Prometheus Therapeutics and Diagnostics, Protagonist, Salix, Shire, 
Sigmoid Pharma, Synergy Pharma, Teva Pharma, TiGenix, Tillotts, UCB, Vertex, VHsquared, Wyeth, 
Zealand, and Zyngenia, outside the submitted work. BGF is CEO and Senior Scientific Director of 
Published in : Lancet (2017), vol. 389, pp. 1699-709 
Status : Postprint (Author’s version)   
 
Robarts Clinical Trials (Western University, London, ON, Canada). WJS reports grants, personal fees, 
and non-financial support from Boehringer Ingelheim during the conduct of the study; grants from 
Exact Sciences, the American College of Gastroenterology, and the Broad Foundation; grants and 
personal fees from Prometheus Laboratories, AbbVie, Amgen, Boehringer Ingelheim, Takeda, Atlantic 
Pharmaceuticals, Janssen, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Genentech, 
Pfizer, Nutrition Science Partners, and Receptos; personal fees from Kyowa Hakko Kirin, Millennium 
Pharmaceuticals, Celgene Cellular Therapeutics, Santarus, Salix Pharmaceuticals, Catabasis 
Pharmaceuticals, Vertex Pharmaceuticals, Warner Chilcott, Cosmo Pharmaceuticals, Ferring 
Pharmaceuticals, Sigmoid Biotechnologies, Tillotts Pharma, Am Pharma BV, Dr August Wolff GmbH & 
Co KG, Avaxia Biologies, Zyngenia, Ironwood Pharmaceuticals, Index Pharmaceuticals, Nestle, 
Lexicon Pharmaceuticals, UCB Pharma, Orexigen, Luitpold Pharmaceuticals, Baxter Healthcare, 
Ferring Research Institute, Novo Nordisk, Mesoblast, Shire, Ardelyx, Actavis, Seattle Genetics, 
Medlmmune (AstraZeneca), ActoGeniX NV, Lipid Therapeutics Gmbh, Eisai, Qu Biologies, Toray 
Industries, Teva Pharmaceuticals, Eli Lilly, Chiasma, TiGenix, Adheron Therapeutics, Immune 
Pharmaceuticals, Celgene, Arena Pharmaceuticals, Ambrx, Akros Pharma, Vascular Biogenics, 
Theradiag, Forward Pharma, Regeneron, Galapagos, Seres Health, Ritter Pharmaceuticals, 
Theravance Biopharma, Palatin, Biogen, and the University of Western Ontario (owner of Robarts 
Clinical Trials), outside the submitted work. WJS reports patents related to the use of topical 
azathioprine to treat inflammatory bowel disorders (US 5 691 343), topical formulations of azathioprine 
to treat inflammatory bowel disorders (US 5,905,081), colonic delivery of nicotine to treat inflammatory 
bowel disease (South African patent 97/1020; US 5,846,983, 5,889,028, and 6,166,044; Mexico patent 
209636; Europe patents 0954337 and 893998; Hong Kong patent HK1019043; China patent 
ZL97192177; Czech patent 293616; Canada patent 2,246,235), the use of azathioprine to treat CD 
(US 5,733,915), azathioprine compositions for colonic administration (New Zealand patent 306062; 
Singapore patent 45647; Australia patent 707168; Czech patent 290428), intestinal absorption of 
nicotine to treat nicotine responsive conditions (Australia patent 718052; US 6,238,689), the use of 
topical azathioprine and thioguanine to treat colorectal adenomas (US 6,166,024), enema and enteric-
coated oral dosage forms of azathioprine (US 6,432,967), a pharmaceutical composition for the 
treatment of inflammatory bowel disease (US 7341741), intestinal absorption of nicotine to treat 
nicotine responsive conditions (Canada patent 2,260,909), and obesity treatment and device (US 
7,803,195 B2). GD'H reports personal fees from Boehringer Ingelheim, during the conduct of the 
study; personal fees from AbbVie, Ablynx, Amakem, AM Pharma, Avaxia, Biogen, Bristol-Myers 
Squibb, Celgene, Celltrion, Cosmo, Covidien, Engene, Ferring, Galapagos, GlaxoSmithKline, Hospira, 
Johnson and Johnson, Medimetrics, Millennium/Takeda, Mitsubishi Pharma, Merck Sharp Dome, 
Mundipharma, Novo Nordisk, Pfizer, Prometheus Laboratories/Nestlé, Receptos, Robarts Clinical 
Trials, Salix, Sandoz, Setpoint, Shire, Teva, Tillotts, TopiVert, Versant, and Vifor, outside the 
submitted work. JP reports personal fees from Boehringer Ingelheim, during the conduct of the study; 
personal fees from AbbVie, Galapagos, Genentech Roche, Pfizer, Takeda, TiGenix, and TopiVert, 
outside the submitted work. AK reports grants, and non-financial support from Boehringer Ingelheim, 
during the conduct of the study; personal fees from Boehringer Ingelheim, Ferring, Genentech, 
GlaxoSmithKline, Hospira, Janssen, Kymab, Second Genome, and VHsquared, outside the submitted 
work. MF reports personal fees and non-financial support from Boehringer Ingelheim, during the 
conduct of the study; grants, personal fees, and non-financial support from Takeda, personal fees and 
non-financial support from AbbVie, Falk, Ferring, Janssen, MSD, and Tillotts; personal fees from 
Chiesi, Mitsubishi Tanabe, and Zeria Pharmaceutical Co., outside the submitted work. EL reports 
grants, personal fees, and non-financial support from AbbVie and MSD; personal fees from Ferring, 
Takeda, Celltrion, Mundipharma, Hospira, and Janssen, outside the submitted work. DF reports 
educational grants, personal fees and non-financial support from AbbVie and MSD; personal fees from 
Amgen, Ferring, Takeda, Mundipharma, Hospira, and Pfizer, outside the submitted work. US reports 
grants from Boehringer Ingelheim, during the conduct of the study; grants from Pfizer, Janssen, 
Roche, Gilead, Salix, and Mitsubishi; personal fees from MSD; non-financial support from Takeda, 
outside the submitted work. MFN reports personal fees from MSD Sharp & Dohme GmbH, PPM 
Services SA, Index Pharmaceuticals AB, Shire GmbH, Boehringer Ingelheim GmbH & Co. KG, 
Published in : Lancet (2017), vol. 389, pp. 1699-709 
Status : Postprint (Author’s version)   
 
Janssen-Cilag GmbH, Pentax Europe GmbH, Tillotts Pharma AG, e.Bavarian Health GmbH, and 
Takeda Pharma GmbH & Co. KG; grants from German Research Council and German Cancer Aid, 
outside the submitted work. In addition, MFN has a patent anti-interleukin-12 therapy in Crohn's 
disease issued. S S reports personal fees from Boehringer Ingelheim, during the conduct of the study; 
personal fees from Boehringer Ingelheim, Medlmmune, and Janssen, outside the submitted work. OD 
and K-JK report no competing interests. PS, CP, BL, SV, SJP, IH, AS, DBH, and WOB are employed 
by Boehringer Ingelheim. PS, SV, SJP, and WOB report a patent BI case 09-0645-US-4pending. 
Acknowledgments 
Editorial assistance in the development of this manuscript was provided by Esther Race and Leigh 
Church of Succint Choice (London, UK) and funded by Boehringer Ingelheim (Ingelheim, Germany). 
We thank Patrick Baum (Boehringer Ingelheim, Ingelheim, Germany) for technical expertise in RNA 
sequencing, Oliver Kleiner (Boehringer Ingelheim, Ingelheim, Germany) for plasma biomarker 
expertise, Richard Vinisko (Boehringer Ingelheim, Ridgefield, CT, USA) for biomarker statistical 
analysis, and Kelly Coble and Steve Norris (Boehringer Ingelheim, Ridgefield, CT, USA) for their 
technical expertise with bioanalytical assays for risankizumab and anti-drug antibody. 
References 
1      Baumgart DC, Sandborn WJ. Crohn's disease. Lancet 2012; 380:1590-605. 
2       Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's 
disease. N Engl J Med 2007; 357: 228-38. 
3     Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's 
disease: results of the ENCORE Trial. Gastroenterology 2007; 132:1672-83. 
4     Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and 
safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled 
trials. Clin Castro Hepatol 2008; 6: 644-53. 
5    Gordon JP, McEwan PC, Maguire A, Sugrue DM, Puelles J. Characterizing unmet medical need 
and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's 
disease: a systematic review and clinician surveys. Eur J Gastroenterol Hepatol 2015; 27: 804-12. 
6   Lichtenstein GR, Sbreu MT, Cohen R, Tremaine W American Gastroenterological Association 
Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel 
disease. Rev Gastroenterol Mex 2006; 71: 351-401. 
7      Neurath MF. IL-23: a master regulator in Crohn disease. Nat Med 2007; 13: 26-8. 
8    Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an 
inflammatory bowel disease gene. Science 2006; 314:1461-63. 
9    Geremia A, Arancibia-Carcamo CV, Fleming MP, et al. IL-23-responsive innate lymphoid cells are 
increased in inflammatory bowel disease. J Exp Med 2011; 208:1127-33. 
10    Campa M, Mansouri B, Warren R, Menter A. A review of biologic therapies targeting IL-23 and IL-
17 for use in mo derate-to-severe plaque psoriasis. Dermatol Ther 2016; 6:1-12. 
11    Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in 
refractory Crohn's disease. N Engl J Med 2012; 367:1519-28. 
12    Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy 
for Crohn's disease. N Engl J Med 2016; 375:1946-60. 
Published in : Lancet (2017), vol. 389, pp. 1699-709 
Status : Postprint (Author’s version)   
 
13    Hueber W, Sands BE, Lewitzky S, et al. Secikunmab, a human anti-IL-17a monoclonal antibody, 
for moderate to severe Crohn's disease: unpected results of a randomised, double-blind placebo-
controlled trial. Gut 2012; 61:1693-700. 
14     Targan SR, Feagan B, Vermeire S, et al. A randomised, double-blind, placebo-controlled phase 
2 study of brodalumab in patients with moderate-to-severe Crohn's disease. Am J Gastroenterol 2016; 
111: 1599-607 
15     Singh S, Kroe-Barrett RR, Canada KA, et al. Selective targeting of the IL23 pathway: generation 
and characterization of a novel high-affinity humanized anti-IL23A antibody. mAbs 2015; 7: 778-91. 
16     Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 
against murine tumors. J Exp Med 1993; 178:1223-30. 
17     Stobie L, Gurunathan S, Prussin C, et al. The role of antigen and IL-12 in sustaining Thl memory 
cells in vivo: IL-12 is required to maintain memory/effector Thl cells sufficient to mediate protection to 
an infectious parasite challenge. Proc Natl Acad Sci USA 2000; 97: 8427-32. 
18     Krueger JG, Ferris LK, Menter A, et al. Anti-IL-23A mAb BI 655066 for treatment of mo de rate-
to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, 
randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2015; 136:116-24. 
19     Levesque BG, Sandborn WJ, Ruel J, et al. Converging goals of treatment of inflammatory bowel 
disease from clinical trials and practice. Gastroenterology 2015; 148: 37-51. 
20     Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic 
efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial 
Study Group. Gastroenterology 1994; 106: 287-96. 
21     Matsuoka K, Kanai T. Mechanism and therapeutic strategy of secondary failure to anti-tumor 
necrosis factor-alpha monoclonal antibody treatment for Crohn's disease. Digestion 2013; 88:17-19. 
22    Terdiman JP, Gruss CB, Heidelbaugh JJ, et al. American Gastroenterological Association 
Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the 
induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology 2013; 
145:1459-63. 
23     Gisbert JP, Marin AC, McNicholl AG, Chaparro M. Systematic review with meta-analysis: the 
efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF 
treatment has failed. Aliment Pharmacol Ther 2015;41:613-23. 
24     Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance 
therapy for Crohn's disease. N Engl J Med 2013; 369: 711-21. 
25    Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal 
antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N 
Engl J Med 1997; 337:1029-35. 
26     Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal 
antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-33. 
27     Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, C-reactive protein 
normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut 2014; 63: 88-95. 
28     Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal 
healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012; 
142:1102-11. 
29     Papp K, Blauvelt A, Bukhalo M, et al. Selective blockade of IL-23pl9 with BI 655066 is 
associated with clinical responses superior to ustekinumab in patients with moderate-to-severe plaque 
psoriasis: Results from a 48-week Phase II study. J Am Acad Dermatol 2016; 74(suppl 1):AB274. 
Published in : Lancet (2017), vol. 389, pp. 1699-709 
Status : Postprint (Author’s version)   
 
30     Ordas I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor 
antagonists in inflammatory bowel disease. Clin Gastro Hepatol 2012; 10:1079-87 
31     Brandse JF, van den Brink GR, Wildenberg ME, et al. Loss of infliximab into feces is associated 
with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology 2015; 149: 
350-55. 
32     Kleinschek MA, Boniface K, Sadekova S, et al. Circulating and gut-resident human Thl7 cells 
express CD161 and promote intestinal inflammation. J Exp Med 2009; 206: 525-34. 
33    van Schie KA, Wolbink GJ, Rispens T Cross-reactive and pre-existing antibodies to therapeutic 
antibodies—effects on treatment and immunogenicity. mAbs 2015; 7: 662-71. 
34     Khanna R, Bouguen G, Feagan BG, et al. A systematic review of measurement of endoscopic 
disease activity and mucosal healing in Crohn's disease: recommendations for clinical trial design. 
Inflamm Bowel Dis 2014; 20:1850-61. 
35    Vuitton L, Marteau P, Sandborn WJ, et al. IOIBD technical review on endoscopic indices for 
Crohn's disease clinical trials. Gut 2016; 20:1447-55. 
 
